Patent · US Active

Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors

US9809624B2 · kind B2 · utility

0Cited by

5References

11Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
IASON GmbH · AT

Inventors

Anne Gruaz · Paris, FR
Didier Pelaprat · Paris, FR
Jacques Barbet · Nantes, FR
Dirk Tourwe · Brussels, BE

Key dates

Filing date	Jul 16, 2010
Grant date	Nov 7, 2017
Priority date	—
Expiry date	Oct 17, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adenocarcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.